Xeljanz Development Plans Scaled Back By Pfizer
This article was originally published in The Pink Sheet Daily
The firm will deprioritize development of the oral JAK inhibitor in Crohn’s disease, ankylosing spondylitis and potentially psoriasis, while focusing on expansion in psoriatic arthritis and ulcerative colitis.
You may also be interested in...
Postmarket trial looking at reduced doses in UC may be difficult to enroll, Pfizer argues; with approval of expanded indication seeming assured, another postmarket question for Xeljanz could look at impact of herpes zoster vaccine.
US FDA's Gastrointestinal Drugs Advisory Committee says higher dosing regimens can be used despite agency worries about safety with long-term use.
US FDA's Gastrointestinal Drugs Advisory Committee will weigh proposed indication as agency appears uncertain whether higher dose can be used as long-term therapy.